Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 6/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | FABP4 | P15090 | 1/20 | 0.34 |
| ▸ | ACHE | P22303 | 2/20 | 0.34 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.33 |
| ▸ | F10 | P00742 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | BTK | Q06187 | 2/20 | 0.33 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9963577 | 0.89 | PTGS2 (0.44) | PTGS2TP53FABP4LMNAGAA | |
| SCHEMBL9963632 | 0.85 | PTGS2 (0.40) | PTGS2ACHEP2RX7GRIN2BGAA | |
| SCHEMBL9963588 | 0.84 | ACHE (0.46) | PTGS2FABP4ACHEP2RX7GRIN2B | |
| SCHEMBL9963581 | 0.83 | PTGS2 (0.42) | PTGS2FABP4ACHEP2RX7GRIN2B | |
| SCHEMBL9963572 | 0.82 | TP53 (0.51) | PTGS2TP53ACHEGRIN2BGAA | |
| SCHEMBL9963583 | 0.82 | PTGS2 (0.42) | PTGS2TP53FABP4LMNAGAA | |
| SCHEMBL9963594 | 0.82 | PTGS2 (0.41) | PTGS2TP53FABP4ACHEP2RX7 | |
| SCHEMBL9963539 | 0.82 | PTGS2 (0.43) | PTGS2FABP4LMNAGAAALDH1A1 | |
| SCHEMBL9963695 | 0.82 | PTGS2 (0.49) | PTGS2FABP4GAAALDH1A1RAB9A | |
| SCHEMBL9963570 | 0.82 | PTGS2 (0.41) | PTGS2ACHEP2RX7LMNAGRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8203001-B2 | Chemical compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-19 | — | — | US | disclosed |
| US-8203001-B2 | Chemical compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-19 | — | — | US | disclosed |
| US-20090258857-A1 | CHEMICAL COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-10-15 | — | — | US | disclosed |
| US-20090258857-A1 | CHEMICAL COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-10-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090258857-A1 | CHEMICAL COMPOUNDS | CCNA1, CCNT1, MKI67 | PTGS2 2872/4885TP53 107/4885FABP4 1794/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.